Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04167514 · ClinicalTrials.gov registry record · Phase 3
Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone
A Phase 3 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 3
- Development phase
- 136
- Enrollment target
NCT04167514 is a Phase 3 study that has completed, run by CSL Behring. The registered enrollment target is 136 participants.
The verdict
NCT04167514, a Phase 3 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 136 participants
- Enrollment target
Study Summary
Study CSL964\_5001 will investigate the efficacy of AAT with corticosteroids compared with corticosteroids alone as first line therapy for patients with high-risk acute GVHD
Interventions
- DRUG Placebo
- BIOLOGICAL Alpha-1 antitrypsin (AAT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2020-01-09 |
| Est. Completion | 2024-06-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04167514
The ClinicalTrials.gov registry entry for NCT04167514 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CSL Behring, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04167514 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04167514 about?
NCT04167514 is a clinical study titled "Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone". Study CSL964\_5001 will investigate the efficacy of AAT with corticosteroids compared with corticosteroids alone as first line therapy for patients with high-risk acute GVHD
What is the current status of trial NCT04167514?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 136 participants. The study started on 2020-01-09. Estimated completion is 2024-06-26.
What interventions are being tested in trial NCT04167514?
The interventions under investigation include: Placebo (DRUG), Alpha-1 antitrypsin (AAT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04167514?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.